(Press-News.org) A new study by investigators from Mass General Brigham examined the effects of policies banning flavored e-cigarettes on adults and young people. Investigators found that e-cigarette use significantly declined among young adults and adults in states that had enacted flavor bans relative to states that did not. However, declines in cigarette smoking also slowed in those states with flavor bans relative to other states—a potential unintended consequence of the bans. Results are published in JAMA Network Open.
“Both e-cigarettes and combustible cigarettes are essentially a source of nicotine for people who may have nicotine dependencies,” said Douglas Levy, PhD, Director of Policy Research at the Tobacco Research & Treatment Center at Massachusetts General Hospital, a founding member of the Mass General Brigham healthcare system. “We're trying to solve the problem of youth vaping, but we need to carefully consider impacts on more harmful combustible cigarette use.”
Flavored e-cigarettes are extremely popular among teens and young adults, raising public health concerns due to the addictive nicotine they contain. To reduce youth vaping, states including Massachusetts, New Jersey, New York, Rhode Island, Maryland and Utah banned the sale of flavored e-cigarettes, with many policies going into place in 2020. Levy, and other researchers at Mass General Brigham evaluated how those laws have influenced e-cigarette and cigarette use in youths and adults.
The study, led by first author David Cheng, PhD, used data from large-scale surveys administered in 50 states and D.C. from 2019 to 2023, tracking changes in the prevalence of tobacco use before (2019) and after (2020-2023) six states introduced flavor bans. Significant decreases in e-cigarette use among young adults ages 18–24 and adults over 25 were found in states with flavor bans relative to trends from other states without the bans. However, increases in cigarette smoking were also found among teenagers and young adults in those same states relative to other states.
Other key stats from the study:
Among young adults (ages 18–24), e-cigarette use declined by 6.7 percentage points in policy states relative to other states in 2022.
Among adults aged 25+, e-cigarette use declined by 1.2 percentage points in policy states relative to other states in 2023.
From 2019 to 2023, youth e-cigarette use declined from 24.1% to 14.0% in policy states, compared to 24.6% to 17.2% in other states.
However, cigarette use declined less in states with flavor bans relative to other states:
For example, in 2021:
Cigarette use among youths was 1.8 percentage points higher than expected in policy states.
Cigarette use among young adults was 3.7 percentage points higher than expected.
The associations between flavor bans and e-cigarette and cigarette use varied by state. Massachusetts saw consistent decreases in vaping associated with the bans across age groups, which could be due to the presence earlier local bans and stronger enforcement. Other states, such as Utah and Maryland, allowed certain exemptions (e.g., menthol flavors or specialty shops), which may have modified the impact of their bans.
One limitation of the study is that it was observational, meaning no experimental manipulation was involved, and unmeasured factors may have contributed to the findings. Additionally, these results reflect the initial experience of the first states to institute flavor restriction policies. The impact of restrictions may change over time for states with existing restrictions and states that newly institute restrictions.
The next step is to identify additional strategies that can curb youth nicotine use without slowing downward trends in cigarette smoking.
Authorship: In addition to Levy and Cheng, Mass General Brigham authors of the study include Abra M. Jeffers, Maeve Stover, Lindsay Kephart, Ginny Chadwick, A. Eden Evins, and Nancy A. Rigotti. Additional authors include Gina R. Kruse of the University of Colorado School of Medicine.
Disclosures: Cheng reported having a pending grant from AstraZeneca outside the submitted work. Kruse reported having family equity ownership in Dimagi, Inc and receiving grants from AstraZeneca administered by the National Comprehensive Cancer Network outside the submitted work. Rigotti reported receiving grants from Achieve Life Sciences, Inc paid to Massachusetts General Hospital and personal fees from Achieve Life Sciences, Inc ending in 2022 and UpToDate outside the submitted work.
Funding: This research was supported by the National Institute on Drug Abuse within the National Institutes of Health (grant R01DA054935).
Paper cited: Cheng, D. et al. “State E-Cigarette Flavor Restrictions and Tobacco Product Use in Youths and Adults.” JAMA Network Open DOI: 10.1001/jamanetworkopen.2025.24184
###
About Mass General Brigham
Mass General Brigham is an integrated academic health care system, uniting great minds to solve the hardest problems in medicine for our communities and the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services. Mass General Brigham is a nonprofit organization committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation’s leading biomedical research organizations with several Harvard Medical School teaching hospitals. For more information, please visit massgeneralbrigham.org.
END
Liver cancer cells thrive on fat, posing a serious risk of cancer diagnosis for millions of people living with fatty liver disease. But researchers at McMaster University in collaboration with Espervita Therapeutics have developed a promising new treatment that helps the immune system attack and destroy these tumours.
The discovery, detailed in a study published in Nature on July 30, 2025, opens new possibilities for slowing tumour growth and empowering the body’s natural defences. This is particularly important, as current treatments for ...
CHICAGO --- Most U.S. adults have a “heart age” several years older than their chronological age — sometimes by more than a decade. And that gap is wider among men and among those with lower incomes or education or who identify as Black or Hispanic, according to a new study led by Northwestern Medicine.
As part of the study, the Northwestern scientists created a free online tool that calculates a person’s “heart age” based on their risk for cardiovascular disease, using routine health data such as blood pressure, cholesterol levels and whether ...
(Toronto, July 30, 2025) JMIR Publications invites submissions to a new theme issue titled “Voice Phenotyping and Vocal Biomarkers” in its open access journal JMIR Biomedical Engineering. The premier, peer-reviewed journal is indexed in PubMed, PubMed Central, Scopus, DOAJ, Sherpa/Romeo, and EBSCO/EBSCO Essentials.
This Call for Papers is seeking high-quality submissions for a new e-collection on a leading-edge field that uses voice and speech analysis to advance the detection, monitoring, and treatment of health conditions.
This e-collection focuses on acoustic and ...
The tumor microenvironment (TME) represents a highly complex system that encompasses cellular components (such as cancer cells, stromal cells, and immune cells) and non-cellular components (such as blood vessels and signaling molecules)[1-3]. These diverse components engage in complex interactions with tumor cells and undergo dynamic changes during tumor progression. Specifically, intratumoral microbial metabolites play an important role on the TME. The metabolic products of these microorganisms encompass a range of bioactive molecules, including lactate, amino acids, short-chain fatty acids (SCFAs), bile acids, trimethylamine N-oxide, and inosine. These metabolites, ...
About The Study: Transparency of evidence supporting Food and Drug Administration (FDA) authorization of artificial intelligence (AI)- and machine learning -based devices for Alzheimer disease and related dementias was limited, precluding effective evaluation of training and validation dataset representativeness. Disease status (i.e., dementia type and distribution), age, and sex were reported for fewer than half of devices, while race and ethnicity data were rarely disclosed, raising uncertainty about real-world generalizability and clinical accuracy in intended populations.
Corresponding Author: To contact the corresponding ...
About 80% of people have the fungus Candida albicans in their gut. Although most of the time it persists unnoticed for years causing no health problems, C. albicans can turn into a dangerous microbe that causes serious diseases in many organs, including the urinary tract, lungs and brain. Understanding how this fungus colonizes the gut is key to preventing it from becoming harmful.
Working with a mouse model, researchers at Baylor College of Medicine and international collaborators have discovered unexpected factors that help C. albicans ...
Recent climate-related crises — from severe storms and flooding to extreme heat — have raised new questions about how local governments communicate the risk of these crises and what they are doing to keep their citizens safe. To better understand what this communication looks like at local level, and the factors that may be shaping it, researchers from Drexel University analyzed climate resilience planning information available on the public-facing websites of 24 coastal communities in New Jersey that are contending with the effects of sea level rise. Their report, recently published in the Journal of Extreme Events, ...
A new technology that harnesses AI to analyze mammograms and improve the accuracy of predicting a woman’s personalized five-year risk of developing breast cancer has received Breakthrough Device designation from the Food and Drug Administration (FDA). Developed by researchers at Washington University School of Medicine in St. Louis, the software has been licensed to Prognosia Inc., a WashU startup company.
The system analyzes mammograms to produce a risk score estimating the likelihood that a woman will develop breast cancer over the next five years. The technology is ...
True or false?
“It is safe to take an over-the-counter medicine to help you sleep, even if you are drunk on alcohol.”
“Driving while high on THC (cannabis) is safe.”
“Using psychedelics is safe for everyone.”
None of those statements is true. But young men who take a passive approach to news and information—consuming whatever flows over their social media transoms—were likely to believe them in a national survey conducted by Washington State ...
The University of Copenhagen is excited to announce Zuber Lawler as a Sponsor of the 12th Aging Research & Drug Discovery Meeting, the world's largest conference on aging research in the biopharmaceutical industry that will transpire on August 25 - August 29, 2025 on-site at the Ceremonial Hall, University of Copenhagen, and online.
“Zuber Lawler demonstrates meticulous attention to detail with a client-first mentality… They offer personalized care from highly intelligent and creative counsel… ...
